Page 22 - GPD-3-1

Gene & Protein in Disease Enhancing fertility with CRISPR

doi: 10.1093/humupd/dmu051 and safety testing of targeted therapies. Toxicol Pathol.
2016;44(3):346-357.
70. Mani S, Ghosh J, Coutifaris C, Sapienza C, Mainigi M.
Epigenetic changes and assisted reproductive technologies. doi: 10.1177/0192623315609688
Epigenetics. 2020;15(1-2):12-25.
82. Kang Y, Chu C, Wang F, Niu Y. CRISPR/Cas9-mediated
doi: 10.1080/15592294.2019.1646572 genome editing in nonhuman primates. Dis Models Mech.
2019;12(10):dmm039982.
71. Park JE, Sasaki E. Assisted reproductive techniques and
genetic manipulation in the common marmoset. ILAR J. doi: 10.1242/dmm.039982
2020;61(2-3):286-303.
83. Madeja Z, Pawlak P, Piliszek A. Beyond the mouse: Non-
doi: 10.1093/ilar/ilab002 rodent animal models for study of early mammalian
development and biomedical research. Int J Dev Biol.
72. Novakovic B, Lewis S, Halliday J, et al. Assisted reproductive
technologies are associated with limited epigenetic 2019;63(3-4-5):187-201.
variation at birth that largely resolves by adulthood. Nature doi: 10.1387/ijdb.180414ap
Communications. 2019;10(1):3922.
84. Choi CQ. CRISPR meets its match. ACS Cent Sci.
doi: 10.1038/s41467-019-11929-9 2021;7(5):699-701.
73. Ramos‐Ibeas P, Heras S, Gómez‐Redondo I, et al. Embryo doi: 10.1021/acscentsci.1c00427
responses to stress induced by assisted reproductive 85. Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal
technologies. Mol Reprod Dev. 2019;86(10):1292-1306.
models in biomedical research: A review. Lab Anim Res.
doi: 10.1002/mrd.23119 2022;38(1):18.
74. Gutási A, Hammer SE, El-Matbouli M, Saleh M. Review: doi: 10.1186/s42826-022-00128-1
Recent applications of gene editing in fish species and 86. Zhong L, Huang Y, He J, et al. Generation of in situ CRISPR-
aquatic medicine. Animals (Basel). 2023;13(7):1250.
mediated primary and metastatic cancer from monkey liver.
doi: 10.3390/ani13071250 Signal Transduct Target Ther. 2021;6(1):411.
75. Farquhar CM, Bhattcharya S, Repping S, et al. Female doi: 10.1038/s41392-021-00799-7
subfertility. Nat Rev Dis Primers. 2019;5:7.
87. Wan H, Feng C, Teng F, et al. One-step generation of p53
doi: 10.1038/s41572-018-0058-8 gene biallelic mutant Cynomolgus monkey via the CRISPR/
Cas system. Cell Res. 2015;25(2):258-261.
76. Uludağ H, Aliabadi HM, Gasiunas G. Editorial: Current
approaches to CRISPR/Cas9 delivery. Front Bioeng doi: 10.1038/cr.2014.158
Biotechnol. 2022;10:1103007.
88. Bai S, Hu M, Yu L, et al. DNAJB7 is dispensable for male
doi: 10.3389/fbioe.2022.1103007 fertility in mice. Reprod Biol Endocrinol. 2023;21(1):32.
77. Onuma A, Fujii W, Sugiura K, Naito K. Efficient mutagenesis doi: 10.1186/s12958-023-01086-6
by CRISPR/Cas system during meiotic maturation of 89. Wolthuis RMF, van de Vrugt HJ, Cornel MC. CRISPR gene
porcine oocytes. J Reprod Dev. 2017;63(1):45-50.
therapy enters the clinic: the future starts now. Ned Tijdschr
doi: 10.1262/jrd.2016-094 Geneeskd. 2021;165:D5955.
78. Chen Y, Chen X, Zhang H, et al. TBC1D21 is an essential 90. Drakopoulou E, Anagnou NP, Pappa KI. Gene therapy
factor for sperm mitochondrial sheath assembly and male for malignant and benign gynaecological disorders: A
fertility. Biol Reprod. 2022;107(2):619-634. systematic review of an emerging success story. Cancers
(Basel). 2022;14(13):3238.
doi: 10.1093/biolre/ioac069
doi: 10.3390/cancers14133238
79. Dai J, Li Q, Zhou Q, et al. IQCN disruption causes
fertilization failure and male infertility due to manchette 91. Atabiekov I, Hobeika E, Sheikh U, El Andaloussi A,
assembly defect. EMBO Mol Med. 2022;14(12):e16501. Al-Hendy A. The role of gene therapy in premature ovarian
insufficiency management. Biomedicines. 2018;6(4):102.
doi: 10.15252/emmm.202216501
doi: 10.3390/biomedicines6040102
80. Wang HQ, Wang T, Gao F, Ren WZ. Application of CRISPR/
Cas technology in spermatogenesis research and male 92. Kretzmann JA, Evans CW, Moses C, et al. Tumour
infertility treatment. Genes (Basel). 2022;13(6):1000. suppression by targeted intravenous non-viral CRISPRa
using dendritic polymers. Chem Sci. 2019;10(33):7718-7727.
doi: 10.3390/genes13061000
doi: 10.1039/c9sc01432b
81. Klymiuk N, Seeliger F, Bohlooly YM, Blutke A, Rudmann DG,
Wolf E. Tailored pig models for preclinical efficacy 93. Zhang W, Liu Y, Zhou X, Zhao R, Wang H. Applications of

Volume 3 Issue 1 (2024) 14 https://doi.org/10.36922/gpd.2701